Kiniksa Pharmaceuticals International, plc is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in London. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $678 million and a profit of $59 million (its filed statements).
Product businessPharmaceutical PreparationsLondonfilings since 20189 of 9 filed
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 7.1 out of ten, 9 of 9 metrics filed: past 7.7 out of ten, present 7.8 out of ten, future 5.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2018. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 9.0 out of ten. +104.8% a year over 5 filed years; profitable in 3 of 5. 90th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 4.2 out of ten. Share count grew 3.9% a year. 0% of cash flow returned. Insiders: 47 sales, 0 purchases. 42nd percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 7.6 out of ten. ROE 10%: 10¢ of profit per shareholder dollar. Leverage 26%: owes 26¢ per asset dollar. 76th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 8.0 out of ten. top 20% of 314 in its family; net margin 8.7%. 80th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 7.9 out of ten. top 21% of 315 in its family for leadership; chief executive since 2018. 79th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 5.8 out of ten. top 42% of 272 in its family for room to expand. 58th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 6.2 out of ten. top 38% of 307 in its family for growth drivers. 62nd percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 4.8 out of ten. bottom 48% of 234 in its family for expectations against reality. 48th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-24 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-28 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-28 (on EDGAR). Newest filing: Form 144, 2026-09-03. Filings on record since 2018. Read from EDGAR 2026-10-12.
Who runs it
Patel, Sanj K (CHAIRMAN & CEO); Ragosa, Mark (CHIEF FINANCIAL OFFICER); Moat, Ross (CHIEF OPERATING OFFICER); Megna, Michael R (CHIEF ACCOUNTING OFFICER); Paolini, John F. (CHIEF MEDICAL OFFICER); Malkani, Dhiraj H (CHIEF STRATEGY OFFICER); Tessari, Eben (CHIEF STRATEGY OFFICER); Quart, Barry D (director); Levy, Richard S (director); Cole, G Bradley (director); and 9 more. 19 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.